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In The Lancet, Jack Cuzick and colleagues report the 
ﬁ rst results from IBIS-II (International Breast cancer 
Intervention Study II),1 in which 3864 postmenopausal 
women at high risk of breast cancer were randomly 
assigned to receive the potent, non-steroidal aroma-
tase inhibitor anastrozole or placebo every day for 
5 years. After a median follow-up of 5 years, 40 (2%) of 
1920 women in the anastrozole group and 85 (4%) of 
1944 in the placebo group had developed breast cancer 
(hazard ratio 0·47, 95% CI 0·32–0·68). This ﬁ nding is 
in keeping with those of other similar studies.2–4 So far, 
unsurprisingly, the investigators have not recorded 
evidence for a diﬀ erence in breast cancer or all-
cause mortality: 18 deaths had been reported in the 
anastrozole group and 17 in the placebo group.1
The design of IBIS-II was essentially pragmatic: women 
enrolled were at increased risk of breast cancer, whether 
because of family history or previous diagnosis of non-
invasive lesions (eg, ductal carcinoma in situ, lobular 
carcinoma in situ, and atypical ductal hyperplasia).1 The 
predicted cumulative incidence of all breast cancers 
after 7 years in the control group (5·6%) reﬂ ects an 
increased risk in the participants, and is in line with 
other similar studies of breast cancer prevention.2,3 All 
the women in IBIS-II had a mammogram and physical 
breast examination at baseline, unless these procedures 
had been done within 12 months of enrolment, 
and then at least every 2 years during the treatment 
period. 78 (62%) of 125 cancers were detected through 
screening. At the end of the 5 years, follow-up was as 
per local practice (including imaging), with no central 
review of imaging from either before or during the 
study, or of the lesions (invasive or otherwise) diagnosed 
before or during the trial.
The issue with studies of pharmacological breast 
cancer prevention is whether there is true prevention 
of clinically signiﬁ cant, life-threatening breast cancers, 
early treatment of tumours overdiagnosed by intrinsic 
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to make the strongest possible case for tuberculosis, push 
it up the political agenda, and secure global commitment 
and leadership that will steer a new path to end 
tuberculosis forever.
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screening programmes, or some mixture of the two. 
The consistent ﬁ nding of an increased eﬀ ect of preven-
tion therapy on hormone-receptor-positive tumours 
supports the prediction made by modelling data that 
pharmacological prevention of breast cancer is actually 
early treatment of extant subclinical tumours.5 With 
two-thirds of the anastrozole beneﬁ t in screen-detected 
cancers, in view of their better outcomes,6 the likelihood of 
an eventual breast cancer mortality beneﬁ t seems small.
Longer follow-up will be important for IBIS-II, as 
the investigators acknowledge, but without protocol-
deﬁ ned procedures after 5 years, complete data capture 
might be a challenge. Although the cumulative incidence 
curves should not be overinterpreted, the annual 
frequency of breast cancer diagnosis in the control group 
seems to decrease from about 1% during the 5-year 
treatment programme to roughly 0·3% thereafter, which 
could suggest less stringent routine mammography or 
poor follow-up, or both. 
Cuzick and colleagues conclude that their results provide 
strong support for the use of anastrozole in high-risk 
postmenopausal women. Indeed, 2013 guidance from 
the UK National Institute of Health and Care Excellence7 
recommends that tamoxifen be oﬀ ered to women at 
high risk of breast cancer. However, the use of primary 
prevention pharmacological therapy in women at 
increased risk of breast cancer is nowhere near universal.8,9 
Will IBIS-II change this situation and, if not, why not?
With the strongest protective eﬀ ect recorded in 
hormone-sensitive and screen-detected breast cancers, 
the overall breast cancer mortality gain with prevention 
therapy could be small. No such gain has been reported 
in any of the pharmacoprevention trials so far.2–4 
Therefore, for any woman considering 5 years’ anti-
oestrogen therapy to reduce her risk of breast cancer 
without evidence to suggest that she will have a longer 
life, the perceived and actual toxicity of this intervention 
becomes important. The ﬁ nancial costs of breast cancer 
chemoprevention might have decreased, but the 
toxicity cost to women has not.
In IBIS-II, many women in both groups reported side-
eﬀ ects associated with oestrogen deprivation: frequency 
of musculoskeletal and vasomotor symptoms was about 
50% or higher in both groups, and roughly a ﬁ fth of 
women had gynaecological adverse events. Although the 
increase in frequency with anastrozole was modest for 
musculoskeletal (6%) and vasomotor (8%) events, more 
than 100–200 additional women had these symptoms in 
the anastrozole group compared with the placebo group—
quite often to a moderate or severe level—to prevent 15 
symptomatically diagnosed breast cancers. Compliance 
with endocrine therapy for invasive breast cancer is 
known to be suboptimum, and the reported frequency 
of possible side-eﬀ ects was higher in IBIS-II than in the 
ATAC study of anastrozole after potentially curative breast 
cancer surgery10 (vasomotor symptoms: 57% of women in 
the anastrozole group in IBIS-II vs 34% of women in the 
anastrozole group in ATAC; musculoskeletal symptoms: 
64% vs 28%), although objective morbidity was more 
similar (fractures: 9% vs 6%; cataracts: 5% vs 3%).
In 2002, Kinsinger and Harris11 noted on the publication 
of the IBIS-I tamoxifen chemoprevention trial: “For 
chemoprevention to ﬁ nd a prominent role in reducing 
the burden of breast cancer, research must develop along 
at least three paths. First, longer-term research must ﬁ nd 
that the reduction in incidence translates into a reduction 
in breast cancer mortality. Second, newer drugs that 
have a better safety proﬁ le need to be developed. Finally, 
better ways are needed to target the drugs to those 
women who will beneﬁ t most.” Unfortunately, although 
Cuzick and colleagues report important data,1 IBIS-II has 
not addressed any of these challenges.
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Single-dose radical cure of Plasmodium vivax: a step closer
Almost 40% of the world’s population is at risk of 
Plasmodium vivax infection, with 70–390 million clinical 
episodes occurring each year.1 Unlike Plasmodium 
falciparum, P vivax forms hypnozoite stages, which can 
lie dormant in the liver for months or even years before 
emerging to cause malaria relapses. The risk, frequency, 
and timing of these relapses vary with the geographical 
location of infection and host immunity.2 The chronic 
relapsing nature of the disease can cause severe 
anaemia, miscarriage in pregnant women, malnutrition, 
and developmental delay in young children; the 
associated morbidity and economic burden of these 
manifestations is considerable.3
A radical cure for malaria requires treatment that targets 
both the erythrocytic and liver stages of infection. For 
more than 60 years, radical cure of P vivax has relied on 
primaquine—the only licensed antimalarial with proven 
hypnozoitocidal activity. However, primaquine has several 
major shortcomings. It can cause severe haemolysis 
in patients with glucose-6-phosphate dehydrogenase 
(G6PD) deﬁ ciency, an X-linked disorder present in 1–40% 
of the population.4 WHO guidelines recommend a 14-day 
primaquine regimen, but since treatment is usually 
unsupervised, adherence is generally poor, limiting 
eﬀ ectiveness and public health beneﬁ t.5 Tafenoquine was 
designed as a synthetic analogue of primaquine with a 
slower elimination time, allowing shorter courses to be 
given. Despite its pragmatic advantages over current 
options, progress in bringing tafenoquine to market has 
been slow. It has been 20 years since the ﬁ rst reports of 
its schizontocidal eﬃ  cacy in rodent malaria6 and 10 years 
since the early clinical studies.7
In The Lancet, Alejandro Llanos-Cuentas and colleagues8 
present a much anticipated comparative study of single-
dose tafenoquine for the radical cure of P vivax. This 
multicentre, double-blind, phase 2b clinical trial randomly 
allocated 329 patients to receive one of six regimens: 
a single dose of 50 mg, 100 mg, 300 mg, or 600 mg 
tafenoquine, 14 days of primaquine (15 mg per day), or 
placebo. All patients received chloroquine for 3 days to 
ensure initial clearance of the erythrocytic stages of the 
parasites. The primary objective was to show superiority 
of chloroquine plus tafenoquine over chloroquine alone, 
as assessed by recurrence of P vivax infection within 
6 months. The results are impressive: 6 months after 
being assigned chloroquine plus tafenoquine 300 mg, 
89·2% (95% CI 77−95) of patients remained free from 
P vivax recurrence compared with only 37·5% (23−52) 
of patients assigned to chloroquine alone. The 600 mg 
dose oﬀ ered little beneﬁ t (91·9% [80−97] eﬃ  cacy) over 
the 300 mg dose, and the lower tafenoquine doses 
were signiﬁ cantly worse (both <58%). As expected, 
the proportion of patients who had recurrent 
P vivax infection after chloroquine monotherapy varied 
substantially between sites, ranging from 10% in India, 
to 44% in Thailand, 83% in Brazil, and 88% in Peru. The 
superiority of tafenoquine 300 mg was apparent at all 
sites except in India, where the sample size was small and 
risk of recurrence low. 
Clinical trials of antirelapse treatment are challenging 
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